#1 Clinical Trials Search in Europe

[68GA]GA-NOTA-AE105

This article discusses clinical trials investigating [68Ga]GA-NOTA-AE105, an imaging tracer used in PET/MRI and PET/CT scans for brain tumors called gliomas. The trials aim to evaluate whether this tracer can visualize gliomas, distinguish between different tumor grades, differentiate tumor progression from treatment effects, and predict patient survival outcomes.

Table of Contents

Overview of Clinical Trials

Clinical research is currently underway to investigate [68Ga]GA-NOTA-AE105 as an imaging tracer for patients with gliomas, which are tumors that develop in the brain and spinal cord[1]. The ongoing Phase 1 trial, registered as NCT02945826, has been authorized and has enrolled 61 patients to evaluate this novel imaging approach[1]. This interventional study represents an important step in developing better diagnostic tools for brain tumor patients.

The tracer [68Ga]GA-NOTA-AE105 is designed to bind to a protein called uPAR (urokinase-type plasminogen activator receptor), which is often found in higher amounts on cancer cells[1]. By attaching a radioactive marker to a molecule that seeks out uPAR, researchers hope to create images that show exactly where tumor cells are located and how aggressive they might be.

What the Trials Are Studying

The clinical trial investigating [68Ga]GA-NOTA-AE105 focuses on several important research questions related to brain tumor imaging and diagnosis[1]. These objectives aim to improve how doctors diagnose, monitor, and treat patients with gliomas.

Visualization of Gliomas

One of the primary goals is to determine whether uPAR-PET imaging with [68Ga]GA-NOTA-AE105 can effectively visualize gliomas[1]. Researchers are examining whether the amount of tracer that accumulates in the tumor on imaging scans directly corresponds to the actual amount of uPAR protein present in the tumor tissue[1]. To verify this relationship, the study compares imaging results with immunohistochemical analysis of tumor tissue samples obtained through stereotactic biopsies or during surgical procedures[1].

Tumor Grade Differentiation

Another key objective is to evaluate whether [68Ga]GA-NOTA-AE105 imaging can distinguish between high-grade gliomas and low-grade gliomas[1]. High-grade gliomas are more aggressive and fast-growing tumors, while low-grade gliomas tend to grow more slowly. The hypothesis is that these different tumor types express different levels of uPAR protein, which would result in different amounts of tracer uptake visible on PET scans[1]. If successful, this could help doctors determine tumor aggressiveness without always needing invasive biopsies.

Distinguishing Recurrence from Treatment Effects

A particularly challenging clinical problem that this trial addresses is differentiating between actual tumor progression or recurrence and post-therapeutic effects[1]. After treatments like radiation therapy or chemotherapy, brain tissue can show changes on standard imaging that look similar to tumor growth, making it difficult for doctors to know whether the cancer has returned or if they are seeing treatment-related changes. The study investigates whether [68Ga]GA-NOTA-AE105 can help solve this problem by showing different uptake patterns based on varying levels of uPAR expression between true tumor tissue and treatment-related changes[1].

Survival Prediction

The trial also examines whether high uptake of [68Ga]GA-NOTA-AE105 in brain tumors is associated with shorter survival times for patients[1]. If higher tracer uptake correlates with worse outcomes, this imaging technique could potentially help doctors predict prognosis and tailor treatment strategies accordingly. This prognostic information could be valuable for treatment planning and for informing patients about their expected outcomes.

Imaging Technology Used

The clinical trial utilizes advanced imaging technologies, specifically uPAR-PET/MR and uPAR-PET/CT scanning[1]. These hybrid imaging approaches combine different imaging modalities to provide comprehensive information about brain tumors.

PET/MRI Imaging

PET/MRI combines positron emission tomography with magnetic resonance imaging[1]. The PET component shows the metabolic activity and tracer uptake in the tumor, while the MRI provides detailed anatomical images of brain structures. This combination offers excellent soft tissue contrast, which is particularly important for brain imaging, along with functional information about tumor biology.

PET/CT Imaging

PET/CT combines positron emission tomography with computed tomography scanning[1]. This approach provides both functional information from the PET scan and anatomical detail from the CT scan. While CT does not provide the same soft tissue contrast as MRI, PET/CT is widely available and offers faster scanning times, making it a practical option for many patients.

How the Tracer Works

The tracer [68Ga]GA-NOTA-AE105 consists of a targeting molecule (AE105) that binds specifically to uPAR, attached to a radioactive isotope (Gallium-68) through a chemical linker (NOTA)[1]. When injected into a patient, the tracer circulates through the bloodstream and accumulates in areas where uPAR is present, particularly in tumor tissue. The radioactive gallium-68 emits signals that are detected by the PET scanner, creating images that show where the tracer has accumulated.

Primary Trial Objectives

The Phase 1 trial has several specific objectives designed to evaluate the clinical utility of [68Ga]GA-NOTA-AE105 imaging in glioma patients[1].

Correlation with Tissue Analysis

A fundamental objective is establishing whether tracer uptake on imaging correlates with actual uPAR expression in tumor tissue[1]. Researchers collect tumor samples through stereotactic biopsies or during surgical procedures and analyze them using immunohistochemical techniques to measure uPAR protein levels[1]. These tissue analysis results are then compared with the tracer uptake patterns seen on PET images to determine if the imaging accurately reflects the biological characteristics of the tumor.

Preoperative Assessment

The trial evaluates whether [68Ga]GA-NOTA-AE105 imaging can provide valuable information before surgery or other treatments[1]. Specifically, researchers are testing whether the imaging can help doctors distinguish between tumor progression or recurrence and post-therapeutic effects before making treatment decisions[1]. This preoperative differentiation capability could help avoid unnecessary surgeries in cases where imaging changes are due to treatment effects rather than actual tumor growth.

Prognostic Value Assessment

An important trial objective is determining whether the level of [68Ga]GA-NOTA-AE105 uptake in brain tumors can predict patient survival[1]. The study examines whether patients with high tracer uptake in their tumors have shorter survival times compared to those with lower uptake[1]. This prognostic information could help guide treatment intensity and provide patients and families with more accurate expectations about disease course.

Patient Population and Enrollment

The Phase 1 clinical trial investigating [68Ga]GA-NOTA-AE105 has enrolled 61 patients with gliomas[1]. This enrollment number is typical for early-phase imaging studies, providing enough participants to evaluate the tracer’s performance across different tumor types and grades.

Study Design

The trial is classified as an interventional study, meaning that participants receive the imaging tracer as part of the research protocol[1]. The study has received authorization to proceed, indicating that regulatory authorities have reviewed and approved the research plan[1]. As a Phase 1 trial, the study focuses on establishing basic safety and feasibility while also gathering preliminary data on the tracer’s ability to image gliomas effectively.

Patient Selection

While specific inclusion and exclusion criteria are not detailed in the available trial information, patients enrolled in this study typically have confirmed or suspected gliomas requiring imaging for diagnosis, treatment planning, or monitoring[1]. The study likely includes patients with various glioma grades and types to evaluate how well the tracer performs across the spectrum of these brain tumors.

Potential Clinical Applications

The research investigating [68Ga]GA-NOTA-AE105 could lead to several important clinical applications if the trial objectives are successfully met[1].

Improved Diagnosis

If the tracer effectively visualizes gliomas and correlates with uPAR expression, it could become a valuable diagnostic tool[1]. Doctors could use [68Ga]GA-NOTA-AE105 imaging to better identify tumor boundaries, which is crucial for surgical planning. More accurate visualization of tumor extent could help surgeons remove more tumor tissue while preserving healthy brain tissue.

Tumor Grading

The ability to differentiate between high-grade and low-grade gliomas based on tracer uptake could reduce the need for invasive biopsies in some cases[1]. This non-invasive grading capability would be particularly valuable for tumors located in areas of the brain where biopsy carries significant risks. Knowing the tumor grade helps doctors recommend appropriate treatment strategies, as high-grade and low-grade gliomas require different therapeutic approaches.

Treatment Monitoring

One of the most challenging aspects of managing glioma patients is determining whether changes on imaging scans represent tumor recurrence or treatment effects[1]. If [68Ga]GA-NOTA-AE105 imaging can reliably make this distinction, it could prevent unnecessary surgeries or treatments in patients whose imaging changes are due to treatment effects rather than tumor growth. Conversely, it could help identify true recurrence earlier, allowing for timely intervention.

Prognostic Information

If high tracer uptake correlates with shorter survival, [68Ga]GA-NOTA-AE105 imaging could provide valuable prognostic information[1]. This information could help doctors and patients make more informed decisions about treatment intensity and help with care planning. Prognostic imaging biomarkers could also be useful in clinical trial design, helping to stratify patients by risk level.

Treatment Planning

Detailed imaging of uPAR expression in gliomas could potentially guide targeted therapies in the future[1]. If certain areas of a tumor show particularly high uPAR expression, these regions might be targeted more aggressively with radiation therapy or other treatments. The imaging could also help identify patients who might benefit from therapies targeting the uPAR pathway.

Trial ID Phase Condition Studied Status Enrollment Study Type Imaging Method
NCT02945826 Phase 1 Glioma (brain tumors) Authorised 61 patients Interventional PET/MRI and PET/CT

FAQ

  • What is [68Ga]GA-NOTA-AE105 being studied for? [68Ga]GA-NOTA-AE105 is being investigated as an imaging tracer for brain tumors called gliomas. Researchers are testing whether it can help doctors see these tumors on PET scans, tell the difference between aggressive and less aggressive tumors, and distinguish actual tumor growth from changes caused by treatment.
  • Who can participate in clinical trials with [68Ga]GA-NOTA-AE105? The current Phase 1 trial enrolled 61 patients with gliomas. These trials typically include patients who need brain tumor imaging to help with diagnosis, treatment planning, or monitoring for tumor recurrence.
  • What phase are the clinical trials investigating [68Ga]GA-NOTA-AE105? The clinical trial investigating [68Ga]GA-NOTA-AE105 for glioma imaging is in Phase 1. This early phase focuses on evaluating the safety and basic effectiveness of the imaging tracer in visualizing brain tumors.
  • What type of imaging is used with [68Ga]GA-NOTA-AE105? The tracer [68Ga]GA-NOTA-AE105 is used with PET/MRI or PET/CT scanning. These advanced imaging techniques combine different types of scans to provide detailed pictures of the brain and any tumors present.
  • What are researchers trying to learn from these trials? Researchers want to determine if [68Ga]GA-NOTA-AE105 can accurately show gliomas on scans, help distinguish high-grade from low-grade tumors, tell the difference between tumor recurrence and treatment effects, and potentially predict how long patients might survive based on tracer uptake in the tumor.

Ongoing Clinical Trials on [68GA]GA-NOTA-AE105

  • Study on Using [68Ga]NOTA-AE105 to Visualize and Differentiate Gliomas in Patients

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Glioma: A type of tumor that occurs in the brain and spinal cord, arising from glial cells which support nerve cells. Gliomas can be low-grade (slower growing) or high-grade (more aggressive).
  • PET scan: Positron Emission Tomography, an imaging test that uses a radioactive tracer to show how tissues and organs are functioning, helping doctors detect diseases like cancer.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique that uses magnetic fields and radio waves to create detailed pictures of organs and tissues inside the body.
  • CT scan: Computed Tomography, an imaging procedure that uses X-rays to create detailed cross-sectional images of the body, helping doctors see inside organs and tissues.
  • uPAR: Urokinase-type Plasminogen Activator Receptor, a protein found on cell surfaces that is often present in higher amounts in cancer cells and may be associated with tumor growth and spread.
  • Tracer: A radioactive substance injected into the body before a PET scan that travels to specific areas and makes them visible on the imaging scan.
  • High-grade glioma: A fast-growing, aggressive type of brain tumor that tends to spread quickly and is more difficult to treat than low-grade gliomas.
  • Low-grade glioma: A slower-growing type of brain tumor that is generally less aggressive and may have a better prognosis than high-grade gliomas.
  • Tumor recurrence: The return of cancer after treatment, when tumor cells that were not completely removed or destroyed begin to grow again.
  • Immunohistochemical analysis: A laboratory technique that uses antibodies to detect specific proteins in tissue samples, helping doctors identify and characterize tumors.
  • Stereotactic biopsy: A minimally invasive procedure that uses 3D imaging to guide a needle precisely to a specific location in the brain to obtain a tissue sample for testing.
  • Post-therapeutic effects: Changes in tissue or organs that occur as a result of cancer treatment, such as radiation therapy or chemotherapy, which can sometimes look similar to tumor growth on imaging scans.

References